Given previous evidence of the efficacy of MLI (5,9,10,[14], [15], [16],[25], [26], [27]), we conducted a proof-of-concept trial to investigate the efficacy of combining EGCG with an intensive MLI for 12 months to prevent cognitive decline in APOE-ɛ4 carriers with SCD. This evidence concerns the gene APOE and Schnyder corneal dystrophy.